🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting over 82 million instances each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in close succession. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP partnered with the drug firm its industry partner to develop it.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Outcomes and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which uses two antibiotics. The study enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Medical professionals treating patients have shared positive views. Access to a single-dose, oral treatment of this kind is hailed as a "game-changer" for public health efforts. This is viewed as essential to alleviate the strain of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.